POTSDAM, GERMANY--(Marketwire - September 30, 2010) - Signature Diagnostics / Signature
Diagnostics Appoints Rainer Kramer to Chief Business Officer and Member of
the Management Board processed and transmitted by Hugin AS. The issuer is
solely responsible for the content of this announcement.
Potsdam, Germany, September 30, 2010 - Signature Diagnostics AG announced
today the appointment of Rainer Kramer as Chief Business Officer. Dr.
Kramer previously held the position of Vice President Corporate Business
Development at Jerini AG, where he was responsible for all licensing,
partnering, and alliance management activities. Before joining Jerini, he
performed various research and business development functions at MorphoSys
AG, Martinsried, and Amgen Inc., Thousand Oaks.
"We are delighted to bring Rainer on board to help us exploit the enormous
potential of Signature's pioneering and best-in-class products for early
detection and prognosis of colorectal cancer," said André Rosenthal,
CEO of Signature. "Signature will launch its first products in early 2011
in certain EU markets, either alone or with commercial partners, and
Rainer's business savvy and deal-making experience make him ideal to help
lead Signature forward in this pivotal next stage."
"I'm very excited to work with Signature's dynamic team to introduce
innovative tests that may change the face of detecting colorectal cancer,"
stated Dr. Kramer. "The potential of these products to significantly
improve both the diagnosis and prognosis of one of the most common cancers
worldwide is far-reaching. By bringing CRC screening to a new level of
accuracy and sensitivity, these tests can detect cancer when it is still
curable, thereby improving survival rate."
Dr. Kramer holds a Diploma in Molecular Biology and a Ph.D from the
Max-Planck-Institute for Neurobiology. Throughout his career in corporate
business development, he contributed or delivered numerous strategic
partnerships and license deals encompassing technology platform and product
deals as well as equity transactions with an aggregate value of several
hundred million Euros. As a member of Jerini's M&A committee, he was
instrumental in the sale of Jerini to Shire in 2008 and was Shire's
appointed principal for the sale of JPT GmbH in 2009.
About Signature Diagnostics AG
Signature Diagnostics is a molecular oncology diagnostics company based in
Potsdam, Germany, focusing on the development and commercialization of
innovative and proprietary diagnostic products for the prognosis and early
detection/screening of colorectal cancer. Signature Diagnostics sponsors
and conducts large prospective, multicenter clinical trials with more than
25 primary care hospitals and several dozen colonoscopy centers in Germany
to discover and validate biomarkers for early detection/screening and
prognosis of colorectal and other cancers. The company's first products,
Predictor C and Detector C, will be launched in early 2011 in its own
ISO15189 certified service laboratory. For more information about
Signature Diagnostics' colorectal cancer tests, please visit
--- End of Message ---
Hermannswerder 20 A Potsdam Germany
Press release (PDF): http://hugin.info/143237/R/1448035/390470.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that: (i) the
releases contained herein are protected by copyright and other applicable
laws; and (ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Signature Diagnostics via Thomson Reuters ONE